Clear Eyes Redness Relief, Lubricant/Redness Reliever Eye Drops
Clear Eyes Redness Relief eye drops lack assurance of sterility.
Moderate risk
Taking it may cause temporary or medically reversible health problems. Serious harm is unlikely.
FDA Class II recall · How risk is rated
What happened
Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company, recalled Clear Eyes Redness Relief Lubricant/Redness Reliever Eye Drops (glycerin 0.25%, naphazoline hydrochloride 0.012%) nationwide in the USA due to lack of assurance of sterility. The recall began September 15, 2026, and was added to the FDA's Enforcement Report on September 23, 2026.
The affected products include 0.5 fl oz (15mL) dropper bottles, including a version with a hang tag, distributed by Medtech Products Inc., Tarrytown, NY.
Summary by Recall Canary from the FDA notice.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
2 products
Match the lot code and NDC listed under your product.
Clear Eyes Redness Relief, Lubricant/Redness Reliever Eye Drops (glycerin 0.25%, naphazoline hydrochloride 0.012%)…
- NDC
- 67172-797-15
- Lot
- RL25G02
- RL25G03
- RL25G04
- RL25H02
- RL25H03
- RL25H04
- RL25K01
- RL25K02
- RL25K03
- RL25K04
- RL25M01
- RL25M02
- RL25M03
- RL25M04
- RL25N01
- RL25N02
- RL25N04
Clear Eyes Redness Relief, Lubricant/Redness Reliever Eye Drops (glycerin 0.25%, naphazoline hydrochloride 0.012%) with…
- NDC
- 67172-797-15
- Lot
- RL25G04
- RL2H02
Details
- Company began the recall
- Sold in
Nationwide in the USA.
- Event ID
- 99909
- Recall numbers
- D-0870-2026 to D-0871-2026
- Company
- Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare companyTarrytown, New York
- Hazard
- Sterility failure
- Recall type
- Voluntary: Firm initiated
- Customers told by
- Letter
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
Summary updated
